Granules India in South Africa

Granules India Expands Global Footprint with Acquisition of Senn Chemicals AG

Hyderabad, India – April 10, 2025

Granules India Limited, a leading pharmaceutical manufacturer, has successfully completed the acquisition of Senn Chemicals AG, a Swiss-based Contract Development and Manufacturing Organization (CDMO) specializing in peptide development and manufacturing. The transaction, valued at 20 million Swiss francs (approximately ₹192.5 crore), was finalized through Granules’ wholly owned subsidiary, Granules Peptides Private Limited. (business-standard.com)

Strategic Expansion into Peptide Therapeutics

This acquisition marks a significant milestone in Granules India’s strategic growth journey, enabling the company to enter the rapidly expanding peptide therapeutics segment. Senn Chemicals’ expertise in liquid-phase and solid-phase peptide synthesis, along with its established CDMO business, provides a strong platform for Granules to develop and manufacture complex active pharmaceutical ingredients (APIs). The integration of Senn’s capabilities is expected to enhance Granules’ presence in regulated markets and strengthen its global footprint. (business-standard.com)

Impact on South African Market

Granules India has a notable presence in South Africa, supplying a range of pharmaceutical products, including paracetamol, as active pharmaceutical ingredients (APIs) and ready-to-consume forms. The acquisition of Senn Chemicals is anticipated to bolster Granules’ capabilities in peptide-based therapeutics, potentially expanding its product offerings in the South African market. By leveraging Senn’s expertise, Granules aims to introduce innovative peptide-based treatments, aligning with the growing demand for advanced therapeutics in South Africa. (pharma.economictimes.indiatimes.com)

Financial Performance and Market Outlook

In the fourth quarter ending March 31, 2025, Granules India reported a 2% increase in revenue from operations, despite facing pricing pressures in key markets like the US and Europe. The company’s profit before exceptional items and tax stood at ₹167 crore, reflecting the challenges posed by competitive pricing dynamics. (pharma.economictimes.indiatimes.com) The strategic acquisition of Senn Chemicals is expected to enhance Granules’ product portfolio and manufacturing capabilities, positioning the company for sustained growth and competitiveness in the global pharmaceutical industry.

Looking Ahead

Granules India’s entry into the peptide therapeutics segment through the acquisition of Senn Chemicals AG underscores its commitment to innovation and expansion into high-growth areas. The integration of Senn’s capabilities is poised to strengthen Granules’ position in the global pharmaceutical market, with potential positive implications for its operations in South Africa and other key markets.

For more information, please visit Granules India’s official website.

Note: This article is based on information available up to April 10, 2025. For the most current updates, please refer to official company communications.